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Summary. Background: Dose tailoring of coagulation factors
requires reliably estimated and reproducible pharmacokinetics
(PK) in the individual patient. Objectives: To investigate the
contribution of both biological and methodological factors to
the observed variability of factor VIII (FVIII) PK, with the
focus on diﬀerences between children and adults, and to
examine the implications for dosing. Patients:D a t af r o m5 2
1–6-year-old and 100 10–65-year-old patients with hemophilia
A( F V I I I£ 2I Ud L
)1) in three clinical studies were included.
Results: In vivo recovery was lower, weight-adjusted clearance
was higher and FVIII half-life was on average shorter in
children than in adults. However, a reduced blood sampling
schedule for children was estimated to account for up to one
half of the total observed diﬀerences. Intrapatient variance in
PK was smaller than interpatient variance in 10–65-year-olds.
Age and ratio of actual to ideal weight only showed weak
relationships with PK parameters. Variance in PK caused large
variance in the calculated dose required to maintain a target
FVIII trough level during prophylactic treatment. Conclusion:
Diﬀerences in blood sampling schedules should be taken into
account when results from diﬀerent PK studies are compared.
However, even with this consideration, PK cannot be predicted
from observable patient characteristics but must be determined
for the individual. Because the inﬂuence of reducing the blood
samplingwasminorincomparisontothetruevariancebetween
patients, a reduced blood sampling protocol can be used. Low
intrapatient variability supports the use of PK measurements
for dose tailoring of FVIII.
Keywords: factor VIII, hemophilia A, pharmacokinetics.
Introduction
Prophylactic treatment of hemophilia A with factor VIII
(FVIII) is based on the assumption that an adequate plasma
level of exogenous coagulation factor will protect the patient
from bleeding. [1–3] The plasma level (or level vs. time curve) of
FVIII achieved after an infusion depends on the dose and on
the patients pharmacokinetic (PK) response to it. Thus,
regardless of whether PK calculations are performed or not,
the clinician must consider interindividual variability in FVIII
PK and adjust the dosing accordingly. Consequently, relation-
ships between patient characteristics (e.g. age and body weight
(BW)) and PK have been sought in order to serve as guidance
to dosing. By application of PK principles, the dosage of FVIII
required to reach any predetermined plasma level can then also
be optimized for each individual patient [4–11].
PatientcharacteristicsthatshowrelationshipswithFVIIIPK
include age-dependent physiological changes [8–10,12–16] and
body size and composition [15,17,18]. Thus, weight-adjusted
clearance (CL) of FVIII (i.e. in mL h
)1 per kg) has generally
beenfoundtodecreasewithageand/orBWduringgrowthfrom
infancy to adulthood,with a corresponding increasein terminal
half-life (t½) [8,12,13,15,16]. However, variance in PK can arise
for both true biological and technical or methodological
reasons. The latter reasons for variance include differences
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  2010 International Society on Thrombosis and Haemostasisamong FVIII concentrates, methods for determining product
potencyandplasmaFVIIIlevels,[7,9,18]anddifferencesamong
protocol designs, especially as regards the choice of blood
sampling times and the ﬁnal data analysis [5,7,19–22].
The initial aim of this study was to examine relationships
between FVIII PK parameters and biological characteristics,
in particular differences between young children and older
children/adults, using data from three prospective studies on a
recombinant FVIII (rFVIII). During the evaluation, method-
ological issues became apparent that merited an investigation
of the effects of the blood sampling schedule and repeated PK
assessments in addition to the inﬂuence of patient characteris-
tics. Consequently, this report examines contributions of both
biological and technical or methodological factors to observed
variability in the PK data from the three studies. Implications
for blood sampling and dosing in practice are also explored.
Methods
Study designs
The PK data from previously treated patients (PTPs) with
moderately severe to severe hemophilia A (FVIII £ 2I Ud L
)1)
were compiled from three clinical studies using ADVATE
 
rAHF-PFM [Antihemophilic Factor (recombinant), Plasma/
Albumin Free Method; Baxter Healthcare Corporation,
Deerﬁeld, IL, USA]:
1 a prospective, multicenter, open-label, Phase 2/3 (pediatric)
study in pediatric PTPs (1–6 years of age) with a PK
evaluation [15];
2 a prospective, multicenter, Phase 2/3 (pivotal) study in PTPs
‡ 10 years of age with two randomized, double-blinded,
crossover PK comparisons [23]; and
3 a prospective, multicenter, open-label, Phase 2/3 (continu-
ation) study with a single-arm evaluation of PK after at least
75 exposure days (EDs) in only patients who completed the
pivotal study.
Patients
Allpatients,ortheirlegallyauthorizedrepresentatives,provided
written informed consent. All 52 patients (1–6 years of age) in
the pediatric study were included in the PK evaluation. Of 111
patients enrolled in the pivotal study, 100 (10–65 years of age)
wereincludedinPKevaluations.Ofthese,34participatedinthe
continuation study and were included in the PK evaluation.
None of the patients had a known history of inhibitors. The
characteristics of the patients are shown in Table 1.
Study procedures and treatment
All 52 patients in the 1–6-year age group received a single PK
infusion with rAHF-PFM [15]. Of 100 patients in the 10–65-
year age group, 16 received one infusion with rAHF-PFM and
83 received two infusions with biologically equivalent rAHF-
PFM products, one manufactured at investigational scale and
the other at commercial scale [23]. Of those patients receiving
two infusions, 49 received infusions between 72 h and 30 days
apart and34 received infusions before andafter at least 75 EDs.
The PK blood sampling schedule was consistent with the
recommendations of the FVIII/FIX Scientiﬁc and Standard-
ization Committee of the International Society on Thrombosis
and Haemostasis (ISTH) that permit a reduced schedule for
children under 5 years of age [19–22]. Doses of FVIII, infusion
information and blood sampling times are given in Table 2.
Pharmacokinetic calculations
FVIIIactivityassayswereconductedatacentrallaboratoryand
PK parameters were essentially calculated as previously
described [23]. The one-stage aPTT-based assay was used, and
FVIIIlevelsareexpressedasFVIIIcoagulantactivity(FVIII:C).
Post-infusion FVIII:C levels were baseline-adjusted by the
proportion of preinfusion to maximum (peak) level; that is,
adjusted FVIII:C = measured FVIII:C · [1 – (pre-infusion
FVIII:C/maximum FVIII:C)]. FVIII:Cdata from at least seven
time points in the 10–65-year age group and at least three time
points in the 1–6-year age group were required for subsequent
PK analyses.The shapeof eachpatients FVIII:Cvs.timecurve
was evaluated by one- or two-phase linear regression [24]. The
rescaled-residualsumsofsquaresofsingle-phaseandtwo-phase
cases were calculated for each patient and the model with the
leastresidualsumwaschosentoyieldanestimateoft1/2.Atleast
ﬁvedatapointswererequiredforatwo-phaseregressionandthe
second phase was based on at least three of these. Incremental
in vivo recovery (recovery) was calculated by a standard proce-
dure [21] from the maximal observed plasma FVIII:C level
(Cmax). Area under the curve (AUC) and area under the ﬁrst
moment curve (AUMC) were estimated by linear trapezoidal
methods,withextrapolationtoinﬁnitetime[7].Weight-adjusted
Table 1 Patient age and ratio weight
1–6-year age group (n = 52) 10–65-year age group (n = 100)
Min 25% Median 75% Max Min 25% Median 75% Max
Age (years) 1.2 2.2 3.5 5.0 6.0 10.1 14.1 18.5 30.4 65.7
Weight (kg) 10.6 13.4 15.7 19.0 27.2 35.0 53.2 68.6 77.3 107.8
Height (cm) 76 91 98 111 121 135 163 172 178 191
Ratio weight* 0.77 0.96 1.04 1.11 1.54 0.71 0.97 1.05 1.20 1.69
*Ratio weight: actual/ideal weight for age. n, number of patients; Min, minimum of range; Max, maximum of range; 25%, 25th percentile; 75%,
75th percentile.
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calculated from dose, AUC and AUMC by standard methods
[7]. All PK parameters are reported using descriptive statistics.
The impact of reducing the sampling schedule, as for the 1–
6-year age group, on PK parameter estimation was evaluated
by removing the 0.25, 0.5, 3, 6, 28 and 32 h postinfusion data
points from the 10–65-year age group and then recalculating
PK parameter values.
Statistical analyses
Variance component analyses were performed to assess
intrapatient and interpatient variance on two repeated PK
measurements. Multivariate linear regression analyses were
performed to investigate the association between PK param-
eters and patients characteristics. Because PK parameters were
not normally distributed, values were log-transformed. The
characteristics used as independent variables were age and ratio
weight. The ratio weight is deﬁned as actual weight divided by
ideal weight for age and was chosen as the most suitable age-
independent body mass measure. Spearmans correlations with
age were calculated for three candidate measurements: body
mass index (BMI), ratio weight, and ratio BMI (= actual
BMI/median BMI for age). Among these, ratio weight showed
least age-dependency and was included in the ﬁnal multiple
regression model. Ideal weight, which is very similar to lean
body mass, was estimated for patients > 18 years as
50 + 0.9 · (height in cm for each cm above 152) kg [25] and
for patients£ 18 years bythesmoothed mediancurves between
weight and age on the NHANES data [26].
Implications of PK estimates for dosing during prophylactic
treatment
The inﬂuence of different estimates of PK parameters (i.e. from
three sampling schedules: 1–6-year-olds with reduced sampling,
10–65-year-olds with full sampling, and 10–65-year-olds with
reduced sampling) on the dosage of FVIII needed to maintain a
1.0 IU dL
)1 trough level was calculated. Regular prophylactic
dosing every 2 days was assumed and the minimum (or trough)
level, Cmin, was calculated using standard one-compartment
PK according to:
Cmin ¼ Dose   IVR  
1
ð1   e k sÞ
  e k s
In this equation, dose is in IU kg
)1, IVR is recovery in
IU dL
)1 per IU kg,
)1 k is the elimination rate constant
(k = ln2/t½), and s is the time interval between doses (i.e.
48 h). The term 1/(1)e
)k·s) accounts for accumulation of
FVIII during multiple dosing (i.e. some FVIII remaining from
previous doses whenever a new dose is given). The dose
required for Cmin =1 . 0I Ud L
)1 was calculated using various
values for recovery and t½. For biphasic FVIII:C vs. time
curves, calculations were performed using the data describing
the terminal phase of the curve. For the calculation of annual
FVIII consumption the median body weights of 16 and 68 kg
were used (for the 1–6- and 1–65-year age groups, respectively).
Results
Patient characteristics and PK parameter values
Baseline patient characteristics are shown in Table 1 and PK
infusionsaredescribedinTable 2.No patient wasexcludeddue
tomissingdatapoints.Accordingtotheprotocol,Cmaxwasonly
measured at the 1-h postinfusion time point for all (52)
assessments in the 1–6-year age group. For patients in the 10–
65-yearagegroupwhohadall10postinfusionsamples(174/184
assessments),Cmaxwasobservedat15 minpostinfusionin75%
(130/174) of the assessments, at 30 min in 21% (36/174), at 1 h
in 3.5% (6/174), and at 3 h in the remaining two assessments.
Table 2 Pharmacokinetic study infusions and pre-infusion FVIII:C level
1–6-year age group (n = 52) 10–65-year age group (n = 100)
Median dose (IU kg
)1) 50 (range: 45–55) 50 (range: 40–62)
Infusion rate Maximum of £ 10 mL min
)1 over £ 5 min
)1
Total number of infusions 52 184
Blood sampling schedule Reduced schedule Full schedule
Median preinfusion time (h) )0.08 ()0.92 to )0.02) )0.12 ()1.67 to 0.00)
0.25 ND 0.25 (0.17–0.40)
0.5 ND 0.50 (0.42–0.83)
1 1.0 (0.9–1.2) 1.0 (0.9–1.4)
3 ND 3.0 (2.9–4.0)
6 ND 6.0 (5.7–7.0)
9 8.1 (7.0–9.8) 9.0 (8.1–10.0)
24 24.0 (22.2–26.0) 24.0 (23.1–25.0)
28 ND 28.0 (27.0–28.5)
32 ND 32.0 (30.0–32.9)
48 48.1 (46.2–49.9) 48.1 (47.0–49.3)
Median preinfusion FVIII:C level (IU dL
)1) <1 (range, <1–5.9; IQR, <1–1.5) <1 (range, <1–47.0; IQR, <1–1.4)
Of 52 patients, each received one infusion. All infusions included all reduced sampling time points. Of 100 patients, 16 received one infusion and
84 received two infusions. One hundred and seventy-four infusions included all full sampling schedule time points; nine were missing one time point
and one was missing two time points. IQR, interquartile range. n, number of patients. ND, not done.
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in the majority (166/174) of study assessments.
According to the curve-ﬁtting criteria (which required at
least ﬁve postinfusion values for two-phase linear regression),
the FVIII:C plasma level vs. time could only be described by
monophasic curves in the 1–6-year age group. In contrast, in
the 10–65-year age group with the full sampling schedule, the
curves were better described by biphasic functions in 163/184
(89%) cases (representative curves are shown in Fig. 1). The
median plasma level of exogenous FVIII:C at 48 h after the
infusion was 2.5 (range: < 1.0–12) IU dL
)1in the 1–6-year age
group and 4.4 (range:< 1.0–23) IU dL
)1in the 10–65-year age
group. PK parameters are summarized in Table 3. Overall,
patients in the older age group showed a lower median weight-
adjusted CL and a longer median t½. Recoveries or Vss could
not be compared directly due to the differences in sampling
times.
Effects of sampling schedule on estimation of PK parameters
Reducing the sampling schedule in the 10–65-year age group to
mimic that in the 1–6-year age group allowed only monophasic
curves to be used to describe FVIII:C vs. time. It also resulted
in lower estimates (P < 0.001) of all ﬁve PK parameters, for
example in the 10–65-year age group the median difference in
t½ between the reduced and full sampling schedules was 0.80
(25th–75th percentiles: 0.38–1.5) h (Table 3). Furthermore,
when differences in PK parameters were compared between the
1–6- and 10–65-year age groups, 47% of the difference in Cmax,
45% of the difference in recovery and 38% of the difference in
t½ disappeared when the same sampling schedule was applied
to both groups of patients.
Variability in PK assessments
For all PK parameters, the proportions of intrapatient (within
the same patient) variance were much smaller than the
proportions of interpatient (among patients) variance between
two infusions that were from 72 h to 30 days apart, as well as
between those that were ‡ 75 EDs apart (Table 4). Weight-
adjusted CL showed the least proportion of intrapatient
variance, while Cmax and recovery showed the greatest
proportions.
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Fig. 1. Representative FVIII:C vs. time curves from two adult patients as
evaluated by one- or two-phase linear regression. When the full sampling
schedule is used, the ﬁtted curve is monophasic for patient A and biphasic
for patient B. With data from the reduced sampling schedule, only
monophasic curves can be ﬁtted for both patients. Key to symbols: open
and ﬁlled circles and dashed line = biphasic ﬁt, ﬁlled circles and solid
lines = monophasic ﬁt.
Table 3 Diﬀerence in median pharmacokinetic parameters between age groups
Parameter
Median (25th–75th percentiles) for each schedule* Diﬀerence in medians Median diﬀerence
Reduced Full Reduced Reduced
1–6- and full
10–65-year
groups
Reduced 1–6-
and reduced
10–65-year
groups
Reduced
10–65- and
full 10–65-year
groups
1–6-year age
group
10–65-year age
group
10–65-year
age group
Maximal FVIII:C§ (IU dL
)1) 92 (83–101) 122 (106–141) 108 (89–127) )30 )16 )13.5
Incremental in vivo recovery
[(IU dL
)1)/(IU kg
)1)]
1.84 (1.64–2.02) 2.42 (2.14–2.74) 2.16 (1.84–2.46) )0.58 )0.32 )0.27
Clearance [mL h
)1 kg
)1] 4.34 (3.39–5.46) 3.26 (2.61–3.98) 3.16 (2.54–3.88) 1.08 1.18 )0.06
Volume of distribution (dL kg
)1) 0.50 (0.45–0.58) 0.48 (0.42–0.54) 0.46 (0.39–0.52) 0.02 0.04 )0.03
Terminal half-life (h) 9.4 (8.1–10.8) 11.2 (9.6–13.4) 10.5 (9.0–12.2) )1.8 )1.1 )0.8
See Table 2 for reduced and full sampling schedules. Calculated from one PK infusion for each of 52 patients, each of which included all reduced
sampling time points. Calculated from one PK infusion for 49 patients and an average of two PK infusions for 51 patients, of which 10 were
missing one or two time points (see Table 2). §Maximal concentration was observed at 15–30 min postinfusion for 96% of the assessments in the
10–65-year age group and was only measured at 1-h postinfusion in the 1–6-year age group.
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Multivariatelinearregressionanalyseswereperformedtoassess
associations among PK parameters and patient characteristics.
Theonlysigniﬁcantcorrelationfoundinthe1–6-yearagegroup
was an increase in t½ with age (P = 0.01), but not with ratio
weight.t1/2wasnotcorrelatedwithageorratioweightinthe10–
65-year age group. However, in this group, Cmax and recovery
signiﬁcantlyincreasedwithbothageandratioweight(P £ 0.03).
In addition, weight-adjusted CL and weight-adjusted Vss signif-
icantly decreased with age and ratio weight (P £ 0.024). All
modelr
2valueswerelow,£ 0.31and£ 0.13inanalysesforthe1–
6-yearand10–65-year age groups,respectively.
Implications for dosing during prophylactic treatment
The inﬂuence of PK estimates on calculated dose requirements
that intend to maintain FVIII levels ‡ 1I Ud L
)1 during a
prophylactic treatment regimen is shown in Table 5. The
recoveries were ﬁxed at the median values for each of the three
groups. Variance in t½ had a large effect on dose requirements
because patients at the lower (25th) percentiles would need
approximately three times as much FVIII as patients at the
higher (75th) percentiles. In contrast, a decrease in recovery
from the upper to the lower percentile would only require a
modest proportional increase in dose (23% and 34%, respec-
tively). Calculations using the terminal parts of the biphasic
curves (compare Fig. 1) yielded almost identical results for the
10–65-year age group.
Discussion
The use of PK for any clinical or practical purpose presupposes
that reported ﬁndings are reproducible and comparable, that
the PK is reasonably stable in an individual and that suitable
methodology is available and applied. This report examines
these assumptions using FVIII PK data from a large cohort of
children and adults. The median PK parameter values in this
cohort were in general agreement with earlier ﬁndings for
rFVIII [9,14,27–29]. In all 152 patients (1–65 years of age) there
was a 5-fold interindividual variation in weight-adjusted CL
(from 1.6 to 7.8 mL h
)1 per kg) and a 4-fold variation in t½
(from 6.7 to 25 h), which gave a good range of data for
investigating causes of variance.
It can be reasonably assumed that a reduced blood sampling
schedule in children would inﬂuence estimates of PK param-
eters [20,22] as well as comparisons of PK parameters between
children and adults. This assumption has to our knowledge
never been tested using actual data. We found that method-
ological inﬂuences were as signiﬁcant as the postulated
biological correlates. Reducing the sampling schedule (from
10 to four postinfusion blood samples) resulted in signiﬁcant
c h a n g e si na l le s t i m a t e so fP Kp a r a m e t e r si nt h eo l d e rc h i l d r e n /
adults. The reduced sampling schedule underestimated Cmax
and recovery, which can be expected because Cmax occurred at
15–30 min postinfusion for 95% of the determinations with the
full sampling schedule and these time points were deleted with
the reduced schedule. Blood samples taken up to 30 min after
the infusion yielded similar Cmax values irrespective of sampling
time. Therefore in clinical practice, recovery samples should be
taken when convenient but within 30 min after the infusion.
Reducing the sampling schedule had only a minor impact on
the estimates of CL and Vss. These parameters are based on
AUC, and thus are more robust estimates compared with
recovery, which is calculated from a single FVIII:C level, and
also compared with t½, which depends on line ﬁtting to various
numbers of data points. In this context it must be pointed out
that these ﬁndings were obtained using the one- or two-phase
linear regression described by Lee et al. [24] and may not have
been precisely the same with application of other curve-ﬁtting
methods.
Irrespective of whether the comparison was made with the
calculations on the full or reduced data set from the 10–65-year
age group, the recovery was lower, weight-adjusted CL was
Table 4 Relative proportion of variances in pharmacokinetic parameters for patients in the 10–65-year age group
Parameter
Percentage of variance between two infusions
3 days to 4 weeks apart (n = 49) At least 75 EDs apart (n = 34)
Intrapatient (%) Interpatient (%) Intrapatient (%) Interpatient (%)
Maximal FVIII:C 36 64 33 67
Incremental in vivo recovery 35 65 39 61
Weight-adjusted clearance 13 87 14 86
Weight-adjusted volume of distribution 24 76 21 79
Terminal half-life 22 78 35 65
Table 5 Calculated dose of FVIII needed to maintain a trough level of
1.0 IU dL
)1 during prophylactic treatment with alternate day dosing
Patient age range
Half-life
(h)
Dose
(IU kg
)1)
FVIII
consumption
(kIU year
)1)
1–6 years 8.1 29.7 87
9.4 16.8 49
10.8 10.6 31
10–65 years
(full sampling)
9.6 17.9 222
11.2 10.8 134
13.4 6.3 79
10–65 years
(reduced sampling)
9.0 17.1 213
10.5 9.8 122
12.2 6.3 78
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Comparing data from the two age groups using the same
sampling schedule abolished substantial proportions of the
apparent difference in Cmax, recovery and t½. These ﬁndings
are consistent with discussions in the ISTH publications [20–22]
on the methodology of PK studies. For product comparison
studies, blood samples should be taken at 15 (or 15 and 30) min
postinfusion in addition to the 1-h sample, while for the
evaluation of prophylaxis in children the reduced sampling
schedule recommended by ISTH may be used. Our ﬁndings
conﬁrm that these two study designs or blood sampling
schedules yield results that are not directly comparable.
Some patients had preinfusion levels exceeding 1 IU dL
)1
FVIII:C (Table 2), which could in some cases be attributed to
inadequate washout periods before administration of the study
dose. However, the proportional baseline-adjustment method
chosen in the data analysis (see Methods section) serves to
subtract the declining FVIII:C level from a previous dose. The
high preinfusion levels in some patients consequently did not
affect the ﬁndings of this study.
In order to use PK parameters for individual dose optimi-
zation they must be reproducible within a patient. Intrapatient
variability in recovery or t½ has been investigated and
compared with interpatient variability in a few studies
[16,17,23,27,30]. In the present report, similar results were
obtained with short- and long-term repeated PK investigations:
with 49 patients who received products that were manufactured
at different facilities, using essentially identical processes and
previously shown to be bioequivalent with respect to AUC and
recovery, [23] within 30 days of each other and with 34 patients
who received thesame product before and after at least 75 EDs.
In general agreement with previous ﬁndings [16,23,27,30],
intrapatient variance was uniformly less than interpatient
variance. Cmax and recovery showed the most intrapatient
variability, followed by weight-adjusted Vss and terminal t½,
while the most robust parameter, weight-adjusted CL, was
highly reproducible. The reasons for these ﬁndings should be
similar to those discussed for sampling reduction (above).
Therefore, as previously pointed out, [7,18,21,22] CL (and by
deﬁnition AUC/dose) are the best parameters to compare
products while, as also discussed before [5,7,18,30], recovery is
of little use for this purpose.
Within each age group, only weak relationships were found
between PK parameters and the biological parameters of age
and ratio weight. In the 1–6-year age group, t½ increased with
age as previously described for these patients [15]. An increase
in t½ may be explained either by a decrease in CL or an
increase in Vss (or a combination of both). In this data set, it
appeared to be a combination of both, but the individual
relationships did not reach statistical signiﬁcance. In the 10–65-
year age group, recovery and Cmax increased, and weight-
adjusted Vss decreased, independently with age as well as with
ratio weight. Importantly, all r
2 values were low, which
indicates that neither age nor ratio weight can be used as
predictors of PK parameters in clinical practice. These must be
determined in each individual patient if required clinically.
The dose estimations shown in Table 5 illustrate the large
impact of variance in PK on the calculated dosing needed to
maintain any predetermined trough level during prophylactic
treatment. They also show that the impact of variance in t½ is
considerable while variance in recovery is of minor importance.
The trough (48-h) level is deﬁned by the terminal part of the
biphasic curve. Consequently, very similar levels, and thus dose
requirements, were estimated when the ﬁrst part of the curve
(including the measured recovery) was ignored.
In summary, comparison of the PK of FVIII between 1–6-
and 10–65-year-old hemophilia A patients demonstrated some
clear relationships with age. However, reduction of the PK
blood sampling schedule could account for up to one half of
the observed difference in some key PK parameters. Conse-
quently, differences in blood sampling schedules should be
taken into consideration when results from PK studies are
compared. However, more important from a dosing point of
view is that patient characteristics such as age and ratio weight
showed only weak relationships with PK. The unexplained
biological variance far exceeded that which could be attributed
to known factors. Therefore, PK for dose tailoring cannot be
predicted from these characteristics, but must be determined in
each individual. The inﬂuence of reducing the blood sampling
was also minor in comparison to the true variance between
patients, both as regards PK parameter values and dose
calculations. This suggests that a limited blood sampling
protocol can be used in practice. Because intrapatient variabil-
ity in PK is lower than interpatient variability, the determined
PK parameters can then be assumed to be representative for
that patient and thus be useful for dose tailoring of FVIII.
Addendum
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